NovoCure Limited

NasdaqGS NVCR

NovoCure Limited Price to Sales Ratio (P/S) on December 30, 2024: 5.63

NovoCure Limited Price to Sales Ratio (P/S) is 5.63 on December 30, 2024, a 112.56% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

NovoCure Limited 52-week high Price to Sales Ratio (P/S) is 6.26 on December 13, 2024, which is 11.07% above the current Price to Sales Ratio (P/S).
NovoCure Limited 52-week low Price to Sales Ratio (P/S) is 2.41 on April 22, 2024, which is -57.17% below the current Price to Sales Ratio (P/S).
NovoCure Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 3.57.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: NVCR

NovoCure Limited

CEO	Mr. Asaf Danziger
IPO Date	Oct. 1, 2015
Location	Jersey
Headquarters	No. 4 The Forum
Employees	1,453
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key trends

Past 5 years